Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 1.00 |
| ▸ | AOC2 | O75106 | 5/20 | 1.00 |
| ▸ | MAOA | P21397 | 5/20 | 1.00 |
| ▸ | AOC3 | Q16853 | 2/20 | 1.00 |
| ▸ | DAO | P14920 | 2/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mofegiline SCHEMBL147813 | 1.00 | MAOB (1.00) | MAOBAOC2MAOAAOC3DAO | |
| Mofegiline SCHEMBL1295041 | 1.00 | MAOB (1.00) | MAOBAOC2MAOAAOC3DAO | |
| Mofegiline SCHEMBL14005358 | 1.00 | MAOB (1.00) | MAOBAOC2MAOAAOC3DAO | |
| Mofegiline SCHEMBL343685 | 0.98 | MAOB (0.96) | MAOBAOC2MAOAAOC3DAO | |
| Mofegiline SCHEMBL125286 | 0.98 | MAOB (0.96) | MAOBAOC2MAOAAOC3DAO | |
| Mofegiline SCHEMBL343686 | 0.98 | MAOB (0.96) | MAOBAOC2MAOAAOC3DAO | |
| SCHEMBL1295016 | 0.84 | MAOB (0.72) | MAOBAOC2MAOAAOC3DAO | |
| SCHEMBL1295522 | 0.84 | MAOB (0.72) | MAOBAOC2MAOAAOC3DAO | |
| SCHEMBL1294767 | 0.84 | MAOB (0.72) | MAOBAOC2MAOAAOC3DAO | |
| SCHEMBL1295015 | 0.84 | MAOB (0.72) | MAOBAOC2MAOAAOC3DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0875499-A2 | Process for the crystallisation of alkali metal salts of diformylamide | HOECHST MARION ROUSSEL, INC. (US) | 1998-11-04 | — | — | EP | claimed |
| US-5679854-A | Process for the preparation of (epsilon)-1-amino-2-(fluoromethylene)-4-(p-fluorophenyl)butane and novel intermediate thereof | HOECHST MARION ROUSSEL, INC. (US) | 1997-10-21 | — | — | US | claimed |
| EP-0642338-B1 | USE OF (E)-2-(p-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE IN THE TREATEMENT OF ALZHEIMER'S DISEASE | MERRELL PHARMA INC (US) | 1997-01-22 | — | — | EP | claimed |
| EP-0720475-A1 | TRANSDERMAL DEVICE CONTAINING (E)-2-(P-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERRELL PHARMACEUTICALS INC. (US) | 1996-07-10 | — | — | EP | claimed |
| WO-1995008325-A1 | TRANSDERMAL DEVICE CONTAINING (E)-2-(P-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERRELL PHARMACEUTICALS INC. (US) | 1995-03-30 | — | — | WO | claimed |
| EP-0642338-A1 | USE OF (E)-2-(p-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE IN THE TREATEMENT OF ALZHEIMER'S DISEASE. | MERRELL DOW PHARMA (US) | 1995-03-15 | — | — | EP | claimed |
| WO-1993024120-A1 | USE OF (E)-2-(p-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE IN THE TREATEMENT OF ALZHEIMER'S DISEASE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-12-09 | — | — | WO | claimed |
| EP-0295604-A1 | (E)-2-(p-Fluorophenethyl)-3-fluoroallylamine | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-12-21 | — | — | EP | claimed |
| US-10576148-B2 | Use of VAP-1 inhibitors for treating fibrotic conditions | BIOTIE THERAPIES CORP. (FI) | 2020-03-03 | — | — | US | disclosed |
| US-20180071388-A1 | USE OF VAP-1 INHIBITORS FOR TREATING FIBROTIC CONDITIONS | BIOTIE THERAPIES CORP. (FI) | 2018-03-15 | — | — | US | disclosed |
| EP-2475387-B1 | VAP-1 INHIBITORS FOR USE IN TREATING FIBROTIC CONDITIONS | BIOTIE THERAPIES CORP (FI) | 2017-11-01 | — | — | EP | disclosed |
| US-9795671-B2 | Use of VAP-1 inhibitors for treating fibrotic conditions | BIOTIE THERAPIES CORP. (FI) | 2017-10-24 | — | — | US | disclosed |
| US-20130195883-A1 | USE OF VAP-1 INHIBITORS FOR TREATING FIBROTIC CONDITIONS | THE UNIVERSITY OF BIRMINGHAM (GB) | 2013-08-01 | — | — | US | disclosed |
| EP-2475387-A1 | USE OF VAP-1 INHIBITORS FOR TREATING FIBROTIC CONDITIONS | Biotie Therapies Corp. (FI) | 2012-07-18 | — | — | EP | disclosed |
| WO-1993024120-A1 | USE OF (E)-2-(p-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE IN THE TREATEMENT OF ALZHEIMER'S DISEASE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993024120-A1 | USE OF (E)-2-(p-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE IN THE TREATEMENT OF ALZHEIMER'S DISEASE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993023023-A1 | METHOD FOR PREVENTING ENDOTHELIUM DAMAGE IN MAMMALS AND FOR ALLEVIATING PAIN ASSOCIATED WITH GOUT AND ARTHRITIS | UNIVERSITY OF SASKATCHEWAN (CA) | 1993-11-25 | — | — | WO | disclosed |
| EP-0330218-A2 | Inhibitors of lysyl oxidase | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0295604-A1 | (E)-2-(p-Fluorophenethyl)-3-fluoroallylamine | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-12-21 | — | — | EP | disclosed |
| EP-0295604-A1 | (E)-2-(p-Fluorophenethyl)-3-fluoroallylamine | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-12-21 | — | — | EP | disclosed |